Stockreport

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile [Yahoo! Finance]

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF favorable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies Patients on Scemblix also had fewer dose reductions and half th [Read more]